NCT05220410View on ClinicalTrials.gov

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

May 12, 2025

Study Completion Date

May 12, 2025

Conditions

Treatment Resistant DepressionSuicidal Ideation

Interventions

DRUG

Psilocybin

Open-Label

Trial Locations (1)

21204

Sheppard Pratt Health System, Baltimore

Sponsors

Collaborators (1)

COMPASS Pathways

All Listed Sponsors

collaborator

COMPASS Pathways

INDUSTRY

lead

Sheppard Pratt Health System

OTHER